[{"orgOrder":0,"company":"Gliknik","sponsor":"First In Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Series C Financing","leadProduct":"Biropepimut-S","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Gliknik","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Gliknik \/ First In Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Gliknik \/ First In Ventures"}]

Find Clinical Drug Pipeline Developments & Deals by Gliknik

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma Manufacturing 2024
                          Not Confirmed
                          Pharma Manufacturing 2024
                          Not Confirmed

                          Details : Funding will help advance Gliknik clinical and pre-clinical programs, including: A randomized double-blind, placebo-controlled phase 2 study of Gliknik immuno-oncology compound biropepimut-S, which is nearing completion.

                          Brand Name : GL-0817

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 24, 2021

                          Lead Product(s) : Biropepimut-S,GM CSF,Cyclophosphamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : First In Ventures

                          Deal Size : $11.5 million

                          Deal Type : Series C Financing

                          blank